News

The Pistoia Alliance, a global, not-for-profit alliance that works to lower barriers to innovation in life sciences R&D, launched a freely accessible toolkit to help companies implement the FAIR (Findable, Accessible, Interoperable, Reusable) guiding principles for data management and...

Freudenberg Medical, a global contract manufacturer of medical device components and pharmaceutical tubing,announces the completion of extractables testing on PharmaFocus® Premium silicone tubing used in bio-pharma fluid processing and single-use applications. Freudenberg contracted with Eurofins Lancaster Laboratories to conduct...

A smartphone diagnostic test for COVID-19 being developed by a University of Utah researcher holds the potential for quick, accurate testing without the need for individuals to go to a healthcare facility. A prototype may be ready within two...

Bristol Myers Squibb announced the presentation of data across its portfolio, aimed at addressing solid tumor and hematologic malignancies in 28 types of cancer, at the upcoming American Society of Clinical Oncology 2020 (ASCO20) Virtual Scientific Program, which will...

Hitachi Chemical Advanced Therapeutics Solutions, LLC (HCATS) and apceth Biopharma GmbH (apceth), have expanded their relationship with bluebird bio with long-term development and manufacturing services agreements for clinical and commercial supply for multiple therapies, including: Late stage drug product...

To accelerate national, multi-institutional efforts focused on mapping coronavirus transmission and epidemiological studies, Thermo Fisher Scientific announces the SARS-CoV-2 GlobalAccess Sequencing Program for research consortia and industry groups battling the spread of the pandemic globally. Under the program, the...

Eli Lilly is moving quickly to get a newly-approved precision oncology treatment for certain lung and thyroid cancers into the hands of patients. Following U.S. Food and Drug Administration approval of Retevmo (selpercatinib) on Friday, Indianapolis-based Eli Lilly said it...